Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07566390 · ClinicalTrials.gov registry record · Phase 1
A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT07566390 is a Phase 1 study that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 48 participants.
The verdict
NCT07566390, a Phase 1 study, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which treatment participants get is decided by chance.
Interventions
- DRUG Placebo
- DRUG NNC0113-5840
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2026-11-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07566390
The ClinicalTrials.gov registry entry for NCT07566390 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07566390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07566390 about?
NCT07566390 is a clinical study titled "A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity". The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which trea...
What is the current status of trial NCT07566390?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2026-05-01. Estimated completion is 2026-11-26.
What interventions are being tested in trial NCT07566390?
The interventions under investigation include: Placebo (DRUG), NNC0113-5840 (DRUG).
Who is sponsoring clinical trial NCT07566390?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.